Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
  2. FDA accelerated review denial is a blow to Spectrum’s poziotinib
  3. Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
  4. Allergan assesses brazikumab in two clinical programmes for IBD
  5. AstraZeneca reports negative top-line results from TULIP 1 trial

Latest Content

Pulmatrix to initiate Phase II trial of Pulmazole

US-based biopharmaceutical firm Pulmatrix is set to launch a Phase II clinical trial of Pulmazole (PUR1900) in the first half of this year following receipt of approval from the US Food and Drug Administration (FDA).

January’s top news stories

Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Women’s health pipeline: profiling the GCPR target class

Health disorders in women can be caused by many abnormalities in the body and represent a very broad therapy area. Drug development for women’s health disorders has lagged behind other therapy areas, and few new therapies have been approved in the past years.

2018: The year’s biggest Drug Development Technology stories

The US National Institutes of Health (NIH) has provided funding for a clinical trial to examine the effectiveness of male contraceptive skin gel NES/T, and GlaxoSmithKline (GSK) has started its Phase III trial evaluating Benlysta (belimumab) in combination with rituximab to treat adult patients with systemic lupus erythematosus (SLE). Drug Development Technology wraps up the key headlines from 2018.

FDA accelerated review denial is a blow to Spectrum’s poziotinib

On December 19, Spectrum Pharmaceuticals’ shares tumbled 31% following the FDA decision to decline the company’s request of a breakthrough therapy designation (BTD) for its clinical candidate EGFR tyrosine kinase inhibitor (TKI) poziotinib for the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top